PARP1 and cancer: Of particular note, pharmacological inhibitors of the BER enzyme PARP1 [poly(ADP-ribose) polymerase 1], such as niraparib, olaparib, and rucaparib, are widely used for targeted cancer therapy (Sulai and Tan, 2018; Patel et al., 2020).